Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Operations (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Cash from Operations for 12 consecutive years, with 85290000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 173.53% to 85290000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 278685000.0 through Dec 2025, down 217.45% year-over-year, with the annual reading at 278685000.0 for FY2025, 217.45% down from the prior year.
  • Cash from Operations hit 85290000.0 in Q4 2025 for Viking Therapeutics, up from 94003000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 6134000.0 in Q1 2024 to a low of 94003000.0 in Q3 2025.
  • Historically, Cash from Operations has averaged 26791700.0 across 5 years, with a median of 15569500.0 in 2022.
  • Biggest five-year swings in Cash from Operations: surged 75.11% in 2024 and later crashed 753.13% in 2025.
  • Year by year, Cash from Operations stood at 12350000.0 in 2021, then grew by 11.53% to 10926000.0 in 2022, then crashed by 61.45% to 17640000.0 in 2023, then plummeted by 76.76% to 31181000.0 in 2024, then plummeted by 173.53% to 85290000.0 in 2025.
  • Business Quant data shows Cash from Operations for VKTX at 85290000.0 in Q4 2025, 94003000.0 in Q3 2025, and 47061000.0 in Q2 2025.